Drugs / Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04991870 | Apr 2023 → Jan 2027 expected | gliosarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03420963 | Aug 2018 → Feb 2026 | bone cancer, cutaneous melanoma, female reproductive system neoplasm, lip and oral cavity carcinoma +7 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03019640 | Oct 2017 → Aug 2021 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cord Blood-derived Expanded Allogeneic Natural Killer Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03019640 ↗ |
| Known as | CB-NK-TGF-betaR2-/NR3C1- | “CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.” NCT04991870 ↗ |
| Modality | Cell therapy | “cord blood-derived expanded allogeneic natural killer cells” NCT03019640 ↗ |
| Route | Intravenous | “Patients receive cord blood-derived expanded allogeneic NK cells IV over 1 hour” NCT03019640 ↗ |